



November, 14 2024

To

**BSE Limited**

The Corporate Relationship Dept.

P.J. Towers, Dalal Street

Mumbai-400 001

Scrip Code: 500214

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block- G,

Bandra Kurla Complex, Bandra (East),

Mumbai-400 051

Scrip Code: IONEXCHANG

Sub: **Submission of Analyst / Investor Presentation**

Dear Sir/ Madam,

Pursuant to Regulation 30(6) read with Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed presentation being made to Analyst / Institutional Investor (Group Meet) to discuss the Financial performance of the Company for the Second Quarter and half year ended September 30, 2024.

The aforesaid information is also disclosed on website of the company i.e. [www.ionexchangeglobal.com](http://www.ionexchangeglobal.com).

Kindly take the information on record.

Thanking You

**Yours faithfully,**

**For Ion Exchange (India) Limited**

MILIND  
DATTATRAYA  
PURANIK

Digitally signed by MILIND  
DATTATRAYA PURANIK  
Date: 2024.11.14 17:29:02  
+05'30'

**Milind Puranik**

**Company Secretary & Compliance Officer**

**ACS-4824**

**Encl: As stated above**

**ION EXCHANGE (INDIA) LTD.** | CIN: L74999MH1964PLC014258

Regd. Office: Ion House, Dr. E. Moses Road, Mahalaxmi, Mumbai - 400011, India.

Board: +91 22 6231 2000 | Fax: +91 22 2493 8737 | E-mail: [ieil@ionexchange.co.in](mailto:ieil@ionexchange.co.in) | Web: [www.ionexchangeglobal.com](http://www.ionexchangeglobal.com)

Offices: Bengaluru | Bhubaneswar | Chandigarh | Chennai | Hyderabad | Kolkata | Lucknow | New Delhi | Pune | Vadodara | Vashi | Visakhapatnam



 **ION EXCHANGE**  
*Refreshing the Planet*

EARNINGS PRESENTATION – Q2/H1-FY25

- Ion Exchange (India) Ltd (Ion Exchange), formed in 1964, is a pioneer in water, wastewater treatment & environment solutions and caters to various industries, institutions, homes & communities.
- Headquartered in Mumbai, the company has 7 manufacturing and assembly facilities across India, 1 manufacturing facility in Portugal and 1 assembly facility each in UAE, Indonesia, Bangladesh and Saudi Arabia . It also has presence across other key geographies.

## BUSINESS & FY24 REVENUE MIX (%) - CONSOLIDATED

- **Engineering (60%)** – Provides comprehensive and integrated services and solutions in water & wastewater treatment including Sea Water desalination, Recycle and Zero liquid discharge plants to diverse industries.
- **Chemicals (29%)** – Provides a comprehensive range of resins, speciality chemicals and customized chemical treatment programmes for water, non-water and specialty applications.
- **Consumer Products (11%)** – Caters to individuals, hotels, spas, educational institutions, hospitals, laboratories, railway and defence establishments providing safe drinking water and a clean environment.

## MARQUEE CLIENTS

- **Industrial** – NTPC, NPC, Reliance, IOCL, JSW, CPCL, L&T, ArcelorMittal, Nippon Steel, Nayara Energy, IRCTC , BHEL, Tata Group.
- **Institutional** – Leela, Military Engineering Services, Taj Hotels, Holiday Inn, Hyatt Regency, Oberoi Hotels, Apollo Hospitals, Escorts Heart Institute, DLF, Puravankara.
- **International** – Cargill, Technip France, Unilever Group, Jurong, Thyssenkrupp (Uhde), Jacobs, Kawasaki, Mitsubishi, PDO Oman, Emirates Steel, IKPP Indonesia, JESA and Hyundai Engineering & MCT Dubai.



FY24: Operating Income\*  
INR 23,479 Mn



FY24: Operating EBITDA\*  
INR 2,720 Mn




FY24: PAT\*  
INR 1,954 Mn

\*Consolidated


# Company Overview

- Ion Exchange was originally formed as a subsidiary of Permutit, UK in 1964. It became a wholly owned Indian company in 1985. The company is currently in its 60<sup>th</sup> Year of operations.
- The company has expanded its footprints globally and possesses a diversified product range. It offers one stop water and non-water treatment solutions catering to diverse segments like infrastructure, industry, institutions, municipalities, homes and communities, urban and rural.
- It offers a wide range of solutions across the water cycle from pre-treatment to process water treatment, wastewater treatment, recycle, zero liquid discharge, sewage treatment, packaged drinking water, sea water desalination etc.
- Ion Exchange is also engaged in manufacturing ion exchange resins, membranes, speciality chemicals for water and wastewater treatment as well as non-water applications.
- It has two facilities for in-house R&D and two applications and testing centers.
- It has over 50 patents to their credit and 100+ products commercialized.
- It has a global presence apart from presence in major cities in India with 36+ sales & service centers and 100+ Channel Partners.
- It exports to Africa, Japan, Middle East, Russia, Southeast Asia, Europe, UK, USA, Canada and neighbouring countries.

## FY24 CONSOLIDATED REVENUE BREAKUP\*



## FY24 CONSOLIDATED GEOGRAPHICAL BREAKUP



# Q2/ H1-FY25 Financial Highlights

## Q2-FY25 Performance (Standalone)

**INR 5,889 Mn**  
Operating Income

**INR 670 Mn**  
Operating EBITDA

**11.38%**  
Operating EBITDA  
Margins

**INR 507 Mn**  
Net Profit

**8.61%**  
PAT Margins

**INR 4.127/Share**  
Diluted EPS

## H1-FY25 Performance (Standalone)

**INR 11,050 Mn**  
Operating Income

**INR 1,276 Mn**  
Operating EBITDA

**11.55%**  
Operating EBITDA  
Margins

**INR 966 Mn**  
Net Profit

**8.74%**  
PAT Margins

**INR 7.856/Share**  
Diluted EPS

## Q2-FY25 Performance (Consolidated)

**INR 6,445 Mn**  
Operating Income

**INR 682 Mn**  
Operating EBITDA

**10.58%**  
Operating EBITDA  
Margins

**INR 506 Mn**  
Net Profit

**7.85%**  
PAT Margins

**INR 4.297/Share**  
Diluted EPS

## H1-FY25 Performance (Consolidated)

**INR 12,120 Mn**  
Operating Income

**INR 1,326 Mn**  
Operating EBITDA

**10.94%**  
Operating EBITDA  
Margins

**INR 954 Mn**  
Net Profit

**7.87%**  
PAT Margins

**INR 8.089/Share**  
Diluted EPS

# Q2/ H1-FY25 Operational Highlights

## ENGINEERING

- Improvement in the order flow during the quarter.
- The domestic enquiry bank remains robust, and we are hopeful that finalizations of some large value opportunities in next few months.
- Increase in turnover largely due to improved execution of some of the large EPC contracts. The momentum is expected to continue in the ensuing quarters.

## CHEMICALS

- The segment continues to record improvement in turnover and margins.
- The Roha Plant expansion for manufacture of Resins is at advanced stage and we expect the commercial production to commence in Q1 FY 25-26.

## CONSUMER PRODUCTS

- Consistent turnover growth being witnessed in this segment on the back of greater penetration and acceptance of the Company's product profile. However, margins remain negative in view of the investments being made in infrastructure.

## ENGINEERING ORDER BOOK AND PIPELINE (As on 30<sup>th</sup> September, 2024)

Engineering projects<sup>^</sup>

~ INR 2,654.38 Cr

Outstanding Sri Lanka

~ INR 174.06 Cr

Outstanding UP SWSM  
& Delhi Jal Nigam

~ INR 752.01 Cr

Total Orderbook

~ INR 3,580.45 Cr

Bid Pipeline

~ INR 8,695 Cr

<sup>^</sup>Excluding Sri Lanka Order, UP SWSM & Delhi Jal Nigam order

An underwater scene with a blue color palette. Sunlight rays penetrate from the top, creating a bright, hazy area. Numerous bubbles of various sizes are scattered throughout the water, with a dense trail of bubbles rising from the bottom center. Two larger, more complex bubble structures are visible in the middle ground.

## FINANCIAL OVERVIEW

# Quarterly Standalone Financial Performance

INCOME STATEMENT (INR MN)	Q2-FY25	Q2-FY24	Y-o-Y	Q1-FY25	Q-o-Q
Operating Income	5,889	4,839	21.7%	5,161	14.1%
Expenses	5,219	4,253	22.7%	4,554	14.6%
Operating EBITDA	670	586	14.3%	607	10.4%
<i>Operating EBITDA Margins (%)</i>	<i>11.38%</i>	<i>12.11%</i>	<i>(73) Bps</i>	<i>11.76%</i>	<i>(38) Bps</i>
Depreciation	98	78	25.6%	94	4.3%
Finance Cost	21	22	(4.5)%	17	23.5%
Other Income	126	104	21.2%	126	NA
PBT	677	590	14.7%	622	8.8%
Tax	170	152	11.8%	164	3.7%
Profit After Tax	507	438	15.8%	458	10.7%
<i>PAT Margins (%)</i>	<i>8.61%</i>	<i>9.05%</i>	<i>(44) Bps</i>	<i>8.87%</i>	<i>(26) Bps</i>
Other Comprehensive Income	(2)	(6)	(66.7)%	(2)	NA
Total Comprehensive Income	505	432	16.9%	456	10.7%
Diluted EPS (INR)#	4.127	3.560	15.9%	3.729	10.7%


#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140)



# Quarterly Standalone Segmental Breakup


## ENGINEERING (INR MN)

R  
E  
V  
E  
N  
U  
E







## CHEMICALS (INR MN)

E  
B  
I  
T



## CONSUMER PRODUCTS (INR MN)



# Half Yearly Standalone Financial Performance


INCOME STATEMENT (INR MN)	H1-FY25	H1-FY24	Y-o-Y
Operating Income	11,050	9,330	18.4%
Expenses	9,774	8,225	18.8%
Operating EBITDA	1,276	1,105	15.5%
<i>Operating EBITDA Margins (%)</i>	<i>11.55%</i>	<i>11.84%</i>	<i>(29) Bps</i>
Depreciation	191	154	24.0%
Finance Cost	38	39	(2.6)%
Other Income	252	201	25.4%
<b>PBT</b>	<b>1,299</b>	<b>1,113</b>	<b>16.7%</b>
Tax	333	286	16.4%
<b>Profit After Tax</b>	<b>966</b>	<b>827</b>	<b>16.8%</b>
<i>PAT Margins (%)</i>	<i>8.74%</i>	<i>8.86%</i>	<i>(12) Bps</i>
Other Comprehensive Income	(5)	(12)	(58.3)%
<b>Total Comprehensive Income</b>	<b>961</b>	<b>815</b>	<b>17.9%</b>
Diluted EPS (INR)#	7.856	6.722	16.9%

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140)

# Half Yearly Standalone Segmental Breakup


## ENGINEERING (INR MN)

R  
E  
V  
E  
N  
U  
E







## CHEMICALS (INR MN)

E  
B  
I  
T



## CONSUMER PRODUCTS (INR MN)



# Quarterly Consolidated Financial Performance


INCOME STATEMENT (INR MN)	Q2-FY25	Q2-FY24	Y-o-Y	Q1-FY25	Q-o-Q
Operating Income	6,445	5,330	20.9%	5,676	13.5%
Expenses	5,763	4,726	21.9%	5,035	14.5%
Operating EBITDA	682	604	12.9%	641	6.4%
<i>Operating EBITDA Margins (%)</i>	<i>10.58%</i>	<i>11.33%</i>	<i>(75 ) Bps</i>	<i>11.29%</i>	<i>(71 ) Bps</i>
Depreciation	109	85	28.2%	104	4.8%
Finance Cost	36	36	NA	29	24.1%
Other Income	144	96	50.0%	111	29.7%
<b>PBT</b>	<b>681</b>	<b>579</b>	<b>17.6%</b>	<b>619</b>	<b>10.0%</b>
Share of Profit of equity accounted Investee	2	11	(81.8)%	4	(50.0)%
Tax	177	166	6.6%	175	1.1%
<b>Profit After Tax</b>	<b>506</b>	<b>424</b>	<b>19.3%</b>	<b>448</b>	<b>12.9%</b>
<i>PAT Margins (%)</i>	<i>7.85%</i>	<i>7.95%</i>	<i>(10) Bps</i>	<i>7.89%</i>	<i>(4) Bps</i>
Other Comprehensive Income	6	(4)	NA	(4)	NA
<b>Total Comprehensive Income</b>	<b>512</b>	<b>420</b>	<b>21.9%</b>	<b>444</b>	<b>15.3%</b>
Diluted EPS (INR)#	4.297	3.585	19.9%	3.792	13.3%

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No of Shares: 43,78,740)


# Quarterly Consolidated Segmental Breakup

## ENGINEERING (INR MN)


R  
E  
V  
E  
N  
U  
E






## CHEMICALS (INR MN)



## CONSUMER PRODUCTS (INR MN)



E  
B  
I  
T



# Half Yearly Consolidated Financial Performance


INCOME STATEMENT (INR MN)	H1-FY25	H1-FY24	Y-o-Y
Operating Income	12,120	10,122	19.7%
Expenses	10,794	9,030	19.5%
Operating EBITDA	1,326	1,092	21.4%
<i>Operating EBITDA Margins (%)</i>	<i>10.94%</i>	<i>10.79%</i>	<i>15 Bps</i>
Depreciation	213	164	29.9%
Finance Cost	66	56	17.9%
Other Income	254	182	39.6%
<b>PBT</b>	<b>1,301</b>	<b>1,054</b>	<b>23.4%</b>
Share of Profit of equity accounted Investee	5	11	(54.5)%
Tax	352	308	14.3%
<b>Profit After Tax</b>	<b>954</b>	<b>757</b>	<b>26.0%</b>
<i>PAT Margins (%)</i>	<i>7.87%</i>	<i>7.48%</i>	<i>39 Bps</i>
Other Comprehensive Income	2	(7)	NA
<b>Total Comprehensive Income</b>	<b>956</b>	<b>750</b>	<b>27.5%</b>
Diluted EPS (INR)#	8.089	6.391	26.6%

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No of Shares: 43,78,740)

# Half Yearly Consolidated Segmental Breakup


## ENGINEERING (INR MN)

R  
E  
V  
E  
N  
U  
E







## CHEMICALS (INR MN)

E  
B  
I  
T



## CONSUMER PRODUCTS (INR MN)



An underwater scene with a blue-green color palette. Numerous bubbles of various sizes are scattered throughout the water. A bright light source from the top center creates a vertical beam of light, illuminating the scene and casting soft shadows. The water surface is visible at the bottom, showing ripples and reflections.

## HISTORICAL FINANCIAL OVERVIEW



# Historical Standalone Financial Performance

INCOME STATEMENT (INR MN)	FY21	FY22	FY23	FY24	H1-FY25
Operating Income	14,018	15,094	18,923	21,800	11,050
Expenses	12,067	13,123	16,544	19,129	9,774
Operating EBITDA	1,951	1,971	2,379	2,671	1,276
<i>Operating EBITDA Margins (%)</i>	<i>13.92%</i>	<i>13.06%</i>	<i>12.57%</i>	<i>12.25%</i>	<i>11.55%</i>
Depreciation	261	268	281	330	191
Finance Cost	99	76	90	67	38
Other Income	368	461	450	470	252
PBT	1,959	2,088	2,458	2,744	1,299
Tax	499	545	607	703	333
Profit After Tax	1,460	1,542	1,851	2,041	966
<i>PAT Margins (%)</i>	<i>10.42%</i>	<i>10.22%</i>	<i>9.78%</i>	<i>9.36%</i>	<i>8.74%</i>
Other Comprehensive Income	9	(15)	(23)	(9)	(5)
Total Comprehensive Income	1,469	1,527	1,828	2,032	961
Diluted EPS (INR) @	11.875	12.544	15.060	16.603	7.856

@Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140)

# Historical Standalone Balance Sheet

PARTICULARS (INR MN)	FY23	FY24	H1-FY25
<b>EQUITIES &amp; LIABILITIES</b>			
<b>Equity</b>			
(A) Equity Share Capital	147	147	147
(B) Other Equity	8,718	10,597	11,373
<b>Total Equity</b>	<b>8,865</b>	<b>10,744</b>	<b>11,520</b>
<b>Non-Current Liabilities</b>			
(A) Financial Liabilities			
(i) Borrowings	157	438	847
(ii) Lease Liabilities	34	87	134
(iii) Other financial Liabilities	87	146	135
(B) Provisions	212	231	231
<b>Total Non – Current Liabilities</b>	<b>490</b>	<b>902</b>	<b>1,347</b>
<b>Current Liabilities</b>			
(A) Financial Liabilities			
(i) Borrowings	271	34	220
(ii) Lease Liabilities	31	33	49
(iii) Trade Payables	5,231	6,508	6,261
(iv) Other Financial Liabilities	362	589	584
(B) Other Current Liabilities	3,989	4,383	4,938
(C) Provisions	57	72	125
(D) Liabilities for current tax (Net)	46	43	92
<b>Total Current Liabilities</b>	<b>9,987</b>	<b>11,662</b>	<b>12,269</b>
<b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b>	<b>19,342</b>	<b>23,308</b>	<b>25,136</b>

PARTICULARS (INR MN)	FY23	FY24	H1-FY25
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
(A) Property, Plant and Equipment	1,680	2,149	2,175
(B) Capital Work-in-progress	420	607	1,332
(C) Right-of-Use Assets	341	357	403
(D) Other Intangible Assets	18	125	144
(E) Financial Assets			
(i) Investments	591	842	849
(ii) Trade Receivables	12	9	9
(iii) Loans	220	220	320
(iv) Other Financial Assets	76	87	78
(F) Other Non-Current Assets	44	242	557
(G) Deferred Tax Assets	104	78	86
<b>Total Non – Current Assets</b>	<b>3,506</b>	<b>4,716</b>	<b>5,953</b>
<b>Current Assets</b>			
(A) Inventories	1,856	1,887	2,529
(B) Financial Assets			
(i) Investments	3	5	5
(ii) Trade Receivables	6,974	9,217	9,541
(iii) Cash & Cash Equivalentts	1,586	1,104	753
(iv) Bank Balances	3,584	4,246	3,690
(v) Loans	443	408	428
(vi) Other Financial Assets	132	142	87
(C) Other current assets	1,258	1,583	2,150
<b>Total Current Assets</b>	<b>15,836</b>	<b>18,592</b>	<b>19,183</b>
<b>GRAND TOTAL – ASSETS</b>	<b>19,342</b>	<b>23,308</b>	<b>25,136</b>

# Historical Consolidated Financial Performance

INCOME STATEMENT (INR MN)	FY21	FY22	FY23	FY24	H1-FY25
Operating Income	14,495	15,769	19,896	23,479	12,120
Expenses	12,472	13,637	17,346	20,759	10,794
Operating EBITDA	2,023	2,132	2,550	2,720	1,326
<i>Operating EBITDA Margins (%)</i>	<i>13.96%</i>	<i>13.52%</i>	<i>12.82%</i>	<i>11.58%</i>	<i>10.94%</i>
Depreciation	277	280	291	364	213
Finance Cost	126	100	92	121	66
Other Income	331	417	411	439	254
PBT	1,951	2,169	2,578	2,674	1,301
Share of Profit of equity accounted Investee	(1)	4	9	15	5
Tax	517	556	637	735	352
Profit After Tax	1,433	1,617	1,950	1,954	954
<i>PAT Margins (%)</i>	<i>9.89%</i>	<i>10.25%</i>	<i>9.80%</i>	<i>8.32%</i>	<i>7.87%</i>
Other Comprehensive Income	(2)	(10)	(17)	(3)	2
Total Comprehensive Income	1,431	1,607	1,933	1,951	956
EPS Diluted (INR) <sup>@</sup>	12.141	13.730	16.595	16.534	8.089

<sup>@</sup>Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No. of Shares- 43,78,740)


# Historical Consolidated Balance Sheet

PARTICULARS (INR MN)	FY23	FY24	H1-FY25
<b>EQUITIES &amp; LIABILITIES</b>			
<b>Equity</b>			
(A) Equity Share Capital	142	142	142
(B) Other Equity	8,193	10,037	10,818
<b>Equity attributable to owners</b>	<b>8,335</b>	<b>10,179</b>	<b>10,960</b>
Non Controlling Interest	23	19	16
<b>Total Equity</b>	<b>8,358</b>	<b>10,198</b>	<b>10,976</b>
<b>Non-Current Liabilities</b>			
(A) Financial Liabilities			
(i) Borrowings	157	1,091	1,526
(ii) Lease liabilities	34	110	157
(iii) Other Financial Liabilities	87	146	135
(B) Provisions	239	261	262
(C) Deferred Tax Liabilities (Net)	8	93	93
(D) Other Non-Current Liabilities	5	4	4
<b>Total Non – Current Liabilities</b>	<b>530</b>	<b>1,705</b>	<b>2,177</b>
<b>Current Liabilities</b>			
(A) Financial Liabilities			
(i) Borrowings	368	285	420
(ii) Lease liabilities	33	38	54
(iii) Trade Payables	5,513	6,946	6,660
(iv) Other Financial Liabilities	404	633	644
(B) Other Current Liabilities	4,071	4,545	5,066
(C) Provisions	66	84	139
(D) Liabilities for current tax (Net)	59	60	110
<b>Total Current Liabilities</b>	<b>10,514</b>	<b>12,591</b>	<b>13,093</b>
<b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b>	<b>19,402</b>	<b>24,494</b>	<b>26,246</b>


PARTICULARS (INR MN)	FY23	FY24	H1-FY25
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
(A) Property, Plant and Equipment	1,707	3,018	3,062
(B) Capital Work-in-progress	420	607	1,332
(C) Right-of-Use Assets	343	383	428
(D) Other Intangible Assets	18	162	182
(E) Goodwill	86	102	102
(F) Investment accounted using Equity Method	48	62	68
(G) Financial Assets			
(i) Investments	47	55	56
(ii) Trade Receivables	45	42	9
(iii) Other Financial Assets	155	158	145
(H) Deferred Tax Assets (Net)	116	85	94
(I) Other Non-Current Assets	120	308	624
(J) Non-Current Tax Assets	18	6	7
<b>Total Non – Current Assets</b>	<b>3,123</b>	<b>4,988</b>	<b>6,109</b>
<b>Current Assets</b>			
(A) Inventories	2,223	2,365	2,963
(B) Financial Assets			
(i) Investments	3	5	5
(ii) Trade Receivables	6,968	9,348	9,816
(iii) Cash & Cash Equivalents	1,754	1,536	1,111
(iv) Bank Balances	3,726	4,343	3,791
(v) Loans	152	79	99
(vi) Other Financial Assets	151	160	108
(C) Current Tax Assets (Net)	0	11	3
(D) Other Current Assets	1,302	1,659	2,241
<b>Total Current Assets</b>	<b>16,279</b>	<b>19,506</b>	<b>20,137</b>
<b>GRAND TOTAL – ASSETS</b>	<b>19,402</b>	<b>24,494</b>	<b>26,246</b>

# Consolidated Financial Performance


## REVENUES (INR MN)




## OPERATING EBITDA (INR MN)




## PAT (INR MN)



## NET DEBT/ EQUITY




## RETURN RATIOS




ROE = Net Profit/Net worth, ROCE = EBIT/Capital Employed

## WORKING CAPITAL DAYS




## 1 YEAR SHARE PRICE MOVEMENT (UP TO 30<sup>th</sup> September 2024)



### PRICE DATA (As on 30<sup>th</sup> September 2024)

Face value (INR)	1.0
Market Price (INR)	638.4
52 Week H/L (INR)	767.0/407.0
Market Cap (INR Mn)	93,632.0
Equity Shares Outstanding (Mn)	146.7
1 Year Avg. trading volume ('000)	460.1

### SHAREHOLDING PATTERN (As on 30<sup>th</sup> September 2024)



# Disclaimer

## Ion Exchange (India) Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Ion Exchange (India) Limited ("Company" or "IONEX" ), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

## Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

**Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.**



For further details please contact our Investor Relations Representatives:

VALOREM ADVISORS

Mr. Anuj Sonpal

Tel: +91-22-49039500

Email: [ion@valoremadvisors.com](mailto:ion@valoremadvisors.com)

A dark, moody photograph of a bouquet of flowers, possibly roses, with the text "THANK YOU" overlaid in white. The background is a deep, dark green or black, with the flowers appearing as soft, out-of-focus shapes in shades of purple and pink. The text is centered and rendered in a clean, white, sans-serif font.

THANK YOU